Doç.Dr. Yasın KUTLU

7.     Yayınlar

  7.1. Uluslararası hakemli dergilerde yayınlanan makaleler (SCI & SSCI & Arts and Humanities)

 1. Kutlu Y, Dae SA, Yilmaz F, Erdem D, Sendur MAN, Akbas S, Senocak Tasci E, Bas O, Dane F, Sakin A, Kaya AO, Aykan MB, Ergun Y, Biter S, Disel U, Korkmaz M, Selcukbiricik F, Kose F, Olmez OF, Bilici A, Demir G, Yalcin S. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study. Cancers (Basel). 2024 Jun 18;16(12):2251. doi: 10.3390/cancers16122251. PMID: 38927957; PMCID: PMC11202017.

 2. Kutlu Y, Cekin R, Aydin SG, Shbair ATM, Bilici A, Arici S, Oven BB, Acikgoz O, Ozcan E, Olmez OF, Cakir A, Seker M. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer. Curr Probl Cancer. 2024 Jun;50:101102. doi: 10.1016/j.currproblcancer.2024.101102. Epub 2024 May 11. PMID: 38735211.

 3. Kutlu Y, Aydin SG, Bilici A, Oven BB, Olmez OF, Acikgoz O, Hamdard J. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy. Medicine (Baltimore). 2023 Apr 14;102(15):e33432. doi: 10.1097/MD.0000000000033432. PMID: 37058061; PMCID: PMC10101285.

 4. Karaalioglu B, Cakir T, Kutlu Y, Seker M, Bilici A. Integrated FDG-PET/CT contribution over cross-sectional imaging in recurrence or progression of pancreaticobiliary neoplasms. Abdom Radiol (NY). 2024 Jan;49(1):131-140. doi: 10.1007/s00261-023-04109-3. Epub 2023 Nov 22. PMID: 37991533.

 5. Hamdard J, Bilici A, Sakin A, Kahraman S, Yasin AI, Kalaci E, Gokmen I, Acikgoz O, Kutlu Y, Sendur MAN, Olmez OF, Seker M. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience. J Chemother. 2025 May;37(3):268-277. doi: 10.1080/1120009X.2024.2358458. Epub 2024 May 27. PMID: 38803194.

 6. Taşçı EŞ, Kutlu Y, Ölmez ÖF, Mutlu AU, Gündoğdu Y, Seyyar M, Şahin E, Çabuk D, Majidova N, Uğurlu İ, Demirci A, Aydın D, Çavdar E, Bayram S, Yıldırım N, Karataş F, Eryılmaz MK, Çağlayan D, Menekşe S, Kut E, Arak H, Keser M, Sunar V, Perkin P, Şakalar T, Oyan B, Sönmez Ö, Özer L, Yıldız İ. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. Expert Opin Pharmacother. 2024 Mar;25(4):477-484. doi: 10.1080/14656566.2024.2337261. Epub 2024 Apr 3. PMID: 38568074.

 7. Yıldırım HÇ, Kutlu Y, Mutlu E, Aykan MB, Korkmaz M, Yalçın S, Şakalar T, Celayir ÖM, Kayıkçıoğlu E, Aslan F, Hafızoğlu E, Altıntaş YE, Keskinkılıç M, Chalabiyev E, Çelebi A, Dursun B, Kapar C, Özen M, Acar Ö, Dülgar Ö, Kut E, Biter S, Kus F, Almuradova E, Erdoğan AP, Saray S, Güven DC, Şimşek ET, Üskent N, Kemal Y, Çakar B, Açıkgöz Ö, Kılıçkap S, Aksoy S. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study. Int J Clin Oncol. 2024 Mar;29(3):258-265. doi: 10.1007/s10147-023-02460-5. Epub 2024 Feb 4. PMID: 38310597.

 8. Goktas Aydin S, Bilici A, Calis E, Kutlu Y, Hamdard J, Muglu H, Fatih Olmez O, Karci E, Acikgoz O. Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer. Int Immunopharmacol. 2023 Nov;124(Pt B):110947. doi: 10.1016/j.intimp.2023.110947. Epub 2023 Sep 22. PMID: 37742369.

 9. Goktas Aydin S, Kutlu Y, Muglu H, Aydin A, Acikgoz O, Hamdard J, Karci E, Bilici A, Olmez OF, Yildiz O. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemother Pharmacol. 2024 Jan;93(1):71-78. doi: 10.1007/s00280-023-04592-x. Epub 2023 Sep 29. PMID: 37773537.

 10. Aydin SG, Olmez OF, Selvi O, Geredeli C, Ozden F, Bilici A, Acikgoz O, Karci E, Kutlu Y, Hamdard J, Aydin A. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data. J Gastrointest Cancer. 2024 Mar;55(1):227-236. doi: 10.1007/s12029-023-00953-0. Epub 2023 Jun 22. PMID: 37347353.

 11. Goktas Aydın S, Kutlu Y, Muğlu H, Acikgoz O, Aydin A, Bilici A, vd. SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT. İst Tıp Fak Derg. 2023;86(2):117-22.

 12. Goktas Aydin S, Bilici A, Olmez OF, Oven BB, Acikgoz O, Cakir T, Basim P, Cakir A, Kutlu Y, Hamdard J. The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer. Breast Care (Basel). 2022 Oct;17(5):470-479. doi: 10.1159/000524446. Epub 2022 May 3. PMID: 36684400; PMCID: PMC9851074.

 13. Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T, Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083. Epub 2022 Jun 23. PMID: 35734870.

 14. Gürbüz M, Kutlu Y, Akkuş E, Köksoy EB, Köse N, Öven BB, Uluç BO, Demiray AG, Erdem D, Demir B, Turhal NS, Üskent N, Akbaş S, Selçukbiricik F, İnal A, Bilici A, Ölmez ÖF, Çabuk D, Ünal Ç, Hızal M, Şendur MAN, Korkmaz M, Karadurmuş N, Ertürk İ, Göksu SS, Tatlı AM, Güven DC, Kılıçkap S, Paksoy N, Aydıner A, Çınkır HY, Özkul Ö, Öztürk A, Ballı S, Kemal Y, Erdoğan AP, Er Ö, Yumuk PF, Demirkazık A. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group. J Cancer Res Clin Oncol. 2022 Dec;148(12):3547-3555. doi: 10.1007/s00432-022-04087-x. Epub 2022 Jun 11. PMID: 35689097; PMCID: PMC11800922.

 15. Aydin Yoldemir, Ş., Arman, Y., Akarsu, M., Altun, O., Dikker, O., Toprak, ID., Ozcan, M., Kalyon, S., Kutlu, Y., Irmak, S., Toprak, Z., Tukek, T. The relationship between insulin resistance, obesity, and endotrophin. Int J Diabetes Dev Ctries 40, 191–195 (2020).

 16. Eruzun H, Toprak İD, Arman Y, Yılmaz U, Özcan M, Kutlu Y, Irmak S, Kutlu O, Yoldemir ŞA, Altun Ö, Çil EÖ, Tükek T. Serum endotrophin levels in patients with heart failure with reduced and mid-range ejection fraction. Eur J Intern Med. 2019 Jun;64:29-32. doi: 10.1016/j.ejim.2019.04.016. Epub 2019 Apr 26. PMID: 31036437.

 17. Kutlu O, Altun Ö, Dikker O, Aktaş Ş, Özsoy N, Arman Y, Özgün Çil E, Özcan M, Aydın Yoldemir Ş, Akarsu M, Toprak İD, Kırna K, Kutlu Y, Toprak Z, Eruzun H, Tükek T. Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease. Med Princ Pract. 2019;28(5):463-469. doi: 10.1159/000500106. Epub 2019 Apr 16. PMID: 30995640; PMCID: PMC6771072.

 18. Toprak Z, Cebeci E, Helvaci SA, Toprak ID, Kutlu Y, Sakin A, Tukek T. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients. Int Urol Nephrol. 2017 Jun;49(6):1041-1047. doi: 10.1007/s11255-017-1556-4. Epub 2017 Mar 2. PMID: 28255639.

 19. Topal A, Akdag G, Yildirim S, Kinikoglu O, Isik D, Yildirim G, Tunbekici S, Kus F, Acarbay A, Guliyev M, Majidova N, Kutlu Y, Erman M, Odabas H, Turan N, Karadurmus N. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study. Medicina (Kaunas). 2025 Mar 12;61(3):490. doi: 10.3390/medicina61030490. PMID: 40142301; PMCID: PMC11943710.

  7.2. Uluslararası diğer hakemli dergilerde yayınlanan makaleler

 1. Toprak, İ., Eruzun, H., Kutlu, Y., Arman, Y., Yumuştutan, P., Yoldemir, Ş. A., ... & Tükek, T. (2022). Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock. Journal of Experimental and Clinical Medicine, 39(1), 1-6.

 2. Arman, Y., Ugurlukisi, B., Yuruyen, G., Akarsu, M., Kose, M., Cil, E. O., Ozcan, M., Saracoglu, B., Toprak, ID., Kutlu, Y., Toprak, Z., Alibeyoglu, A., Yoldemir, S., Altun, O., Tukek, T. (2016). The effect of blood glucose regulation on ironmetabolism and hepcidin in uncontrolled type 2 diabetic patients. Int J Clin Exp Med, 9(2), 3869-76.

 3. Yürüyen, G., Toprak, İ. D., & Kutlu, Y. (2019). Adult vaccination awareness in physicians. Bosphorus Medical Journal, 6(3), 89-93.

 4. Kutlu, Y., Toprak, I. D., Gökden, Y., Eruzun, H., Arman, Y., Yoldemir, Ş. A., ... & Tükek, T. (2021). The relationship between sTREM-1 and activation of inflammatory bowel diseases. Journal of Istanbul Faculty of Medicine, 84(3), 318-323.

  7.3. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler

  7.4. Yazılan uluslararası kitaplar veya kitaplarda bölümler

 1. KUTLU, Y., & BİLİCİ, A. (2022). İmmünoterapilerin Endokrin Yan Etkileri ve Yönetimi. Turkiye Klinikleri Medical Oncology-Special Topics, 15(1), 30-36.

 2. KUTLU, Y., & ÖLMEZ, Ö. F. (2022). İmmünoterapilerin Karaciğer Yan Etkileri ve Yönetimi. Turkiye Klinikleri Medical Oncology-Special Topics, 15(1), 17-23.

  7.5. Ulusal hakemli dergilerde yayınlanan makaleler

 1. Kutlu, Y., Aydın, S. G., Bilici, A., Ölmez, Ö., Acikgoz, O., Hamdard, J., ... & Muğlu, H. (2023). Erken evre triple negatif meme kanserinde sağkalım sonuçları ve prognostik faktörler: Tek merkez deneyimi. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 49(3), 355-360.

 2. Kutlu, Y., Bilici, A., Ölmez, Ö., Hamdard, J., Karcı, E., & Açıkgöz, Ö. (2024). Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Neoadjuvan Tedavilerin Etkinliği: Tek Merkez Deneyimi. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 50(3), 419-423.

 3. Aydın, S. G., Açıkgöz, Ö., Kutlu, Y., Bilici, A., Hamdard, J., Ölmez, Ö. F., & Yıldız, Ö. (2021). Real-life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-small Cell Lung Cancer. Acta Haematologica Oncologica Turcica.

 4. Açıkgöz, Ö., Aydın, S. G., Bilici, A., Kutlu, Y., Muglu, H., Karcı, E., ... & Yıldız, Ö. The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients. Acta Haematologica Oncologica Turcica.

 5. Oven, B. B., Okten, I. N., Bilici, A., Yasin, A. I., Koca, S., Yuzugullu, E., ... & Gumus, M. (2024). Is Clinical Risk Score a Useful Predictive Marker of Early Recurrence Among Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors?. Eurasian Journal of Medical Investigation, 8(2).

 6. Akdogan, O., Sutcuoglu, O., Tunali, D., Divrikoglu, D., Gurbuz, A. F., & Kutlu, Y. (2024). Multicenter Real-World Experience from the Turkish Oncology Group: Sotorasib in KRAS G12C-Mutated NSCLC. Eurasian Journal of Medical Investigation, 8(4), 274.

  7.6. Ulusal bilimsel toplantılarda sunulan ve bildiri kitabında basılan bildiriler

  7.7. Diğer yayınlar